Empowered Patient Podcast

Jeff Stein, President and CEO, Cidara Therapeutics talks about  their antifungal platform rezafungin now in Phase 3 clinical development to address the needs of the vulnerable population of patients hospitalized for something else who get a life-threatening fungal infection in the hospital. Jeff also explains their Cloudbreak Antiviral Conjugates platform that is being used to target influenza and COVID-19.  Cidara is not developing vaccines or monoclonal antibodies rather long-acting drugs that are virucidal and that recruit the immune system to clean up the infection. He also clearly describes the differences between fungi and viruses. @CidaraThera @JeffStein #coronavirus #COVID19 #influenza #fungalinfections #antifungal #antiviral Cidara.com Download the transcript

Dr. Barbara Klencke, Chief Development Officer, Sierra Oncology talks about the development of momelotinib for myelofibrosis, a rare blood cancer.  Momelotinib's unique mechanism of action allows it to address all three key symptoms of myelofibrosis, including the debilitating anemia which can be exacerbated by currently available therapies.  The Phase 3 MOMENTUM Clinical Trial evaluating momelotinib for patients with MF is currently recruiting globally.  To learn more: momentumtrial.com #myelofibrosis #JAKInhibitor #ClinicalTrial #RareCancer SierraOncology.com Download the transcript here

Robert Ferguson, nutritionist, author, Health Ambassador to StayHealthy, and creator of DietFreeLife talks about the risk factors and pre-existing health inequalities in the African American community that have led to a high rate of infection from COVID-19.  Robert is particularly focused on excess body fat and the impact of what we eat on diabetes, cancer and hypertension. He emphasizes the need to be more health conscious and to resist peer pressure, questionable sources of health information and diet fads. @dietfreelife #COVID19 #StayHealthy #dietfreelife DietFreeLife.com Download the transcript here

Andreas Boeckl, founder, Dispersa Labs is bringing to the market Sula, breathable cannabis, which is inhaled from measured doses using a device that does not require combustion.  This approach to dosing medical cannabis for specific conditions like neurological disorders, stress, anxiety, PTSD, and pain provides much faster relief than edible cannabis and allows for more flexibility for where the cannabis can be administered.  Andreas also emphasizes the value of this solution for researchers who are studying the use of cannabinoids. @breathesula  #cannabis  #BreatheSula  #PTSD #cannabinoids Breathesula.com Download the transcript here

Laurent Levy, CEO, Nanobiotix talks about using nanoparticles and nanotechnology to destroy cancer cells by bringing a physics perspective to drug development.  The Nanobiotix technology has demonstrated improvement in the efficacy of radiation therapy for patients with soft tissue sarcoma, with an intention to expand across oncology, reducing the side effects and potentially reducing duration of the radiation. #nanobiotix #nanomedicine #cancer #radiationtherapy Nanobiotix.com Download the transcript here  

Nancy Hornberger, EVP, ElectrifAi, worked with IBM and the Watson Group earlier in her career. She brings expertise about data and the health care industry to a company that is using advanced machine learning and artificial intelligence to drive profit improvement, increase performance and reduce risk. We talk about the role of ML and Ai in helping to balance system demands by managing healthcare providers and staff and streamlining processes by reducing the mundane work of looking at raw data and images so that clinicians can make better and faster diagnostic decisions. @ElectrifAi #Ai #ML #COVID19 ElectrifAi.net Download the transcript here

Dr. Werner Rein, Chief Medical Officer, Theranexus shines a light on their evolving understanding of central nervous and neurological system diseases, the discovery of the glial system in the brain and the connection between the glial cells and neurons, and the drive to find compound combinations that can be modulated to treat sleep-wake disorder, cognitive decline and chronic pain. #CNS #glialcells #neurology Theranexus.com Download the transcript here

Dr. Andrea Madrigrano is a general surgeon with an expertise in breast cancer at the Rush University Medical Center in Chicago.  Dr. Madrigrano shines a light on how hospitals have determined what are non-essential surgeries in these times of the COVID virus, how women are dealing with delayed surgeries related to their breast cancer, alternative therapies that are buying some time for women while they wait for restrictions to lift, and the opportunity for research comparing results from current innovations with more traditional approaches. @Madrigrano_am #breastcancer #cancer #COVID19 Download the transcript here  

Daniel Cohen, Founder, Pharnext discusses how the French biopharma company is using its artificial intelligence (AI) driven platform to identify drugs that have already been approved which can be used in combination to fight COVID-19.  Dr. Cohen who lead Pharnext as CEO for over a decade has recently left that role to become Chairman of Pharnext's Scientific Advisory Board in order to focus on his true passion--maximizing the potential of Pharnext's Pleotherapy platform. #pharnext #pleotherapy #COVID19 #drugdiscovery #AI Pharnext.com Download the transcript

Maurice Zauderer, CEO, Vaccinex discusses pepinemab, the antibody drug being developed by Vaccinex for treatment of Huntington's disease, Alzheimer's disease and lung cancer.  Maurice also touches on the relationship between neurodegenerative diseases and cancer, and the commonalities that allow for a treatment like pepinemab to have a potential benefit in both therapeutic areas. @vaccinex $VCNX #immunotherapy #rarediseases #cancer Vaccinex.com Download the transcript here